Patrick Gendron

Patrick Gendron

Auto-generated profile, based on publicly available information

Patrick Gendron

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CLCéline M. Laumont
Céline M. Laumont
KVKrystel Vincent
Krystel Vincent
LHLeslie Hesnard
Leslie Hesnard
ÉAÉric Audemard
Éric Audemard
ÉBÉric Bonneil
Éric Bonneil
Claude PerreaultClaude Perreault
Claude Perreault
A proteogenomic method identifies potentially actionable tumor-specific antigens and shows that most of them are not coded by classic exons.

19 March 2012 in Genes & Development
Verified
Journal Article
Closed access
PDF file
CSCamille Simon
Camille Simon
JCJalila Chagraoui
Jalila Chagraoui
JKJana Krosl
Jana Krosl
PGPatrick Gendron
Patrick Gendron
BWBrian Wilhelm
Brian Wilhelm
GSGuy Sauvageau
Guy Sauvageau
In this study, we show the high frequency of spontaneous γδ T-cell leukemia (T-ALL) occurrence in mice with biallelic deletion of enhancer of zeste homolog 2 (Ezh2). Tumor cells show little residual H3K27 trimethylation marks compared with controls. EZH2 is a component of the PRC2 Polycomb group protein complex, which is associated with DNA methyltransferases. Using next-generation sequencing, we identify alteration in gene expression levels of EZH2 and acquired mutations in PRC2-associated genes (DNMT3A and JARID2) in human adult T-ALL. Together, these studies document that deregulation of EZH2 and associated genes leads to the development of mouse, and likely human, T-ALL.

21 April 2016 in Blood
Verified
Journal Article
Closed access
PDF file
CPCaroline Pabst
Caroline Pabst
ABAnne Bergeron
Anne Bergeron
VLVincent-Philippe Lavallée
Vincent-Philippe Lavallée
JYJonathan Yeh
Jonathan Yeh
PGPatrick Gendron
Patrick Gendron
FBFrédéric Barabé
Frédéric Barabé
Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy, which is initiated and driven by a rare fraction of leukemia stem cells (LSCs). Despite the difficulties to identify a common LSC phenotype there is increasing evidence that high expression of stem cell gene signatures is associated with poor clinical outcome. Identification of functionally distinct subpopulations in this disease is therefore crucial to dissect the molecular machinery underlying LSC self-renewal. Here, we combined Next-Generation-Sequencing (NGS) technology with in vivo assessment of LSC frequencies and identified the adhesion G-protein coupled receptor 56 (GPR56) as a novel and stable marker for human LSCs for the majority of AML samples. High GPR56 expression was significantly associated with high-risk genetic subgroups and poor outcome. Analysis of GPR56 in combination with CD34 expression revealed engraftment potential of GPR56+ cells in both the CD34- and CD34+ fractions thus defining a novel LSC compartment independent of the CD34+CD38- LSC phenotype.

1 April 2016 in Cell Reports
Verified
Journal Article
Open access
ZWZhen Wang
Zhen Wang
QPQinghua Pan
Qinghua Pan
PGPatrick Gendron
Patrick Gendron
WZWeijun Zhu
Weijun Zhu
FGFei Guo
Fei Guo
CLChen Liang
Chen Liang
Cas9 cleaves specific DNA sequences with the assistance of a programmable single guide RNA (sgRNA). Repairing this broken DNA by the cell's error-prone non-homologous end joining (NHEJ) machinery leads to insertions and deletions (indels) that often impair DNA function. Using HIV-1, we have now demonstrated that many of these indels are indeed lethal for the virus, but that others lead to the emergence of replication competent viruses that are resistant to Cas9/sgRNA. This unexpected contribution of Cas9 to the development of viral resistance is facilitated by some indels that are not deleterious for viral replication, but that are refractory to recognition by the same sgRNA as a result of changing the target DNA sequences. This observation illustrates two opposite outcomes of Cas9/sgRNA action, i.e., inactivation of HIV-1 and acceleration of viral escape, thereby potentially limiting the use of Cas9/sgRNA in HIV-1 therapy.

1 May 2001 in Journal of Molecular Biology
Verified
Journal Article
Closed access
PGPatrick Gendron
Patrick Gendron
SLSébastien Lemieux
Sébastien Lemieux
FMFrançois Major
François Major

1 October 2010 in Cell
Verified
Journal Article
Closed access
DADariel Ashton-Beaucage
Dariel Ashton-Beaucage
CUChristian M. Udell
Christian M. Udell
HLHugo Lavoie
Hugo Lavoie
CBCaroline Baril
Caroline Baril
MLMartin Lefrançois
Martin Lefrançois
MTMarc Therrien
Marc Therrien